Rectal cancer breakthrough: could a new drug combo save your rectum?

NCT ID NCT06758830

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of chemotherapy and radiation (total neoadjuvant therapy, or TNT) can shrink rectal tumors enough so that some patients can avoid surgery and instead be monitored closely. About 400 adults with early-stage rectal cancer will be randomly assigned to receive TNT followed by a watch-and-wait approach, or to have surgery first. The goal is to see if the non-surgical approach leads to similar survival and quality of life, while preserving the rectum.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity Fatigue Low Anterior Resection Syndrome Postoperative Complications radiation injury rectal cancer rectal neoplasm rectum adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nacional Cancer Institute

    RECRUITING

    Vilnius, 08660, Lithuania

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact